Premium
Is medullary carcinoma of the breast hormone dependent?
Author(s) -
Patel J. K.,
Nemoto T.,
Dao T. L.
Publication year - 1983
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930240410
Subject(s) - medicine , medullary cavity , tamoxifen , adrenalectomy , oophorectomy , hormone , bilateral adrenalectomy , carcinoma , endocrine system , medullary carcinoma , oncology , estrogen , breast cancer , urology , surgery , gynecology , cancer , thyroid carcinoma , hysterectomy , thyroid
From 1951 to 1981, 22 patients with metastatic medullary carcinoma of the breast were treated with hormonal therapies at Roswell Park Memorial Institute. Bilateral oophorectomy was performed in 6 premenopausal patients, and none had objective response, although one patient did have stable diseases for 7 months. Three of these patients subsequently underwent bilateral adrenalectomy and none responded. Thirteen of 16 postmenopausal patients underwent bilateral adrenalectomy and only one had an objective response of 4 months. Eight of 22 patients recived additive hormones, and one patient was treated with Tamoxifen. There was no objective response to these therapies. From this study, it appears that medullary carcinoma of the breast is less often responsive to endocrine therapy, and this finding correlates well with the recent data showing lower frequency of estrogen receptor‐positive tumors in these patients.